# Whole exome sequencing and polygenic risk assessment for kidney functions and clinical management in both hospital-based cohort and population-based Asian cohorts

**Authors:** Min-Rou Lin, I-Wen Wu, Wan-Hsuan Chou, Yung-Feng Lin, Kuan-Yu Hung, Kaname Kojima, Kosuke Shido, Kengo Kinoshita, Wei-Chiao Chang, Mai-Szu Wu

PMC · DOI: 10.1186/s12929-025-01168-0 · 2025-08-06

## TL;DR

This study explores the genetic factors contributing to kidney disease in Taiwan using whole exome sequencing and finds that rare genetic variants and polygenic scores can predict disease risk and progression.

## Contribution

The study identifies novel rare pathogenic variants and confirms the predictive power of polygenic scores for kidney disease in a Taiwanese population.

## Key findings

- Rare pathogenic variants in genes like PKD1 and COL4A4 were found to contribute to kidney disease susceptibility.
- Polygenic scores for ESKD showed strong predictive utility, outperforming comorbidities like diabetes in predicting kidney function decline.

## Abstract

Taiwan has the highest prevalence of chronic kidney disease (CKD) and end-stage kidney disease (ESKD) globally, making them major public health concerns with significant morbidity, mortality, and healthcare burden. While genetic risk factors for kidney disease have been identified in previous studies, the contribution of rare genetic variants remains unclear.

This study utilized whole-exome sequencing (WES) to investigate the role of missense rare variants in CKD and ESKD susceptibility. Genomic data from 500 Taiwanese individuals at Taipei Medical University Hospital were included based on strict clinical diagnostic criteria, comprising 200 CKD cases, 200 ESKD cases, and 100 healthy controls. Independent validation was performed using ESKD Asian cohorts from the All of Us Research Program (AoU) (N = 222) and the Tohoku Medical Megabank Organization (ToMMo) (N = 140).

We identified rare pathogenic variants in known monogenic kidney disease genes, including PKD1 and COL4A4, confirming their role in disease susceptibility. We replicated GWAS-reported genes such as SPI1, RIN3, FTO, SIPA1L3, and EEF1E1, highlighting their contribution through both common and rare variants. Beyond previously reported genes, we identified novel rare pathogenic variants in PEX1, GANAB, DYNC2H1, and PROKR2. Pathway enrichment analysis suggested that ciliopathies, inflammation, and metabolic dysfunction may contribute to kidney disease progression. Furthermore, the polygenic score (PGS) for ESKD demonstrated strong predictive utility for kidney function, with high genetic risk having a greater influence than comorbidities such as diabetes and overweight. The prediction power of ESKD PGS was further confirmed in the AoU Asian population.

This study provides novel insights into the genetic architecture of CKD and ESKD in the Taiwanese population, utilizing a hospital-based cohort with strict clinical diagnostic criteria to ensure precise phenotype classification. We propose that individuals with high genetic risk may benefit from earlier interventions, while those with lower PGS may be better managed through lifestyle modifications targeting comorbidities. The findings highlight the importance of preventive strategies and precision medicine in kidney disease management.

The online version contains supplementary material available at 10.1186/s12929-025-01168-0.

## Linked entities

- **Genes:** PKD1 (polycystin 1, transient receptor potential channel interacting) [NCBI Gene 5310], COL4A4 (collagen type IV alpha 4 chain) [NCBI Gene 1286], SPI1 (Spi-1 proto-oncogene) [NCBI Gene 6688], RIN3 (Ras and Rab interactor 3) [NCBI Gene 79890], FTO (FTO alpha-ketoglutarate dependent dioxygenase) [NCBI Gene 79068], SIPA1L3 (signal induced proliferation associated 1 like 3) [NCBI Gene 23094], EEF1E1 (eukaryotic translation elongation factor 1 epsilon 1) [NCBI Gene 9521], PEX1 (peroxisomal biogenesis factor 1) [NCBI Gene 5189], GANAB (glucosidase II alpha subunit) [NCBI Gene 23193], DYNC2H1 (dynein cytoplasmic 2 heavy chain 1) [NCBI Gene 79659], PROKR2 (prokineticin receptor 2) [NCBI Gene 128674]
- **Diseases:** chronic kidney disease (MONDO:0005300), end-stage kidney disease (MONDO:0004375)

## Full-text entities

- **Genes:** FTO (FTO alpha-ketoglutarate dependent dioxygenase) [NCBI Gene 79068] {aka ALKBH9, BMIQ14, GDFD, IFEX9}, PROKR2 (prokineticin receptor 2) [NCBI Gene 128674] {aka GPR73L1, GPR73b, GPRg2, HH3, KAL3, PKR2}, COL4A4 (collagen type IV alpha 4 chain) [NCBI Gene 1286] {aka ATS2, BFH, BFH1, CA44}, RIN3 (Ras and Rab interactor 3) [NCBI Gene 79890], GANAB (glucosidase II alpha subunit) [NCBI Gene 23193] {aka G2AN, GIIA, GIIalpha, GLUII, PKD3}, SPI1 (Spi-1 proto-oncogene) [NCBI Gene 6688] {aka AGM10, OF, PU.1, SFPI1, SPI-1, SPI-A}, PEX1 (peroxisomal biogenesis factor 1) [NCBI Gene 5189] {aka HMLR1, PBD1A, PBD1B, ZWS, ZWS1}, EEF1E1 (eukaryotic translation elongation factor 1 epsilon 1) [NCBI Gene 9521] {aka AIMP3, P18}, SIPA1L3 (signal induced proliferation associated 1 like 3) [NCBI Gene 23094] {aka CTRCT45, SPAL3, SPAR3}, PKD1 (polycystin 1, transient receptor potential channel interacting) [NCBI Gene 5310] {aka PBP, PC1, Pc-1, TRPP1, eliosin}, DYNC2H1 (dynein cytoplasmic 2 heavy chain 1) [NCBI Gene 79659] {aka ATD3, DHC1b, DHC2, DNCH2, DYH1B, SRPS2B}
- **Diseases:** metabolic dysfunction (MESH:D008659), inflammation (MESH:D007249), ESKD (MESH:D007676), overweight (MESH:D050177), CKD (MESH:D051436), kidney disease (MESH:D007674), diabetes (MESH:D003920), ciliopathies (MESH:D000072661)

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12330128/full.md

---
Source: https://tomesphere.com/paper/PMC12330128